Large Cap Biotechnology
Stocks Ranked by
Market Capitalization
Large Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 32 large cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $10B and $200B — worth a combined $862B.
The largest by market cap are Vertex Pharmaceuticals (VRTX) at $140B, Regeneron Pharmaceuticals (REGN) at $85.8B and argenx (ARGX) at $63.8B.
Among institutional investors, Revolution Medicines (RVMD) drew the most net new fund positions in Q2 2026: 243 funds opened new positions, taking total fund holders up 176 (34%) quarter-over-quarter.
- Combined market cap: $862B across 32 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Vertex Pharmaceuticals (VRTX), $140B market cap.
- Most net new fund positions in Q2 2026: Revolution Medicines (RVMD), +176 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.